EUVIMEDEUVIMED entdecken
Crossref

Molecular disparity of HLA‐DPB1 is associated with the development of subsequent solid cancer after allogeneic hematopoietic stem cell transplantation

Jun Zou iD, Piyanuch Kongtim, Betül Oran iD, Samer A Srour iD, Uri Greenbaum, Yudith Carmazzi, Gabriela Rondon, Stefan O Ciurea iD, Qing Ma, Elizabeth J Shpall, Richard E Champlin, Kai Cao

Cancer · 2023

DOI: 10.1002/cncr.34671 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer, 2023. Verfasst von Jun Zou und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Graft vs Host Disease. Die Arbeit nennt 53 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

An increased incidence of subsequent solid cancers (SSCs) has been reported in long‐term survivors of allogeneic hematopoietic stem cell transplantation (allo‐HSCT), and SSC is associated with inferior mortality and morbidity. Previous studies showed that the incidence of SSC is significantly higher in those who underwent allo‐HSCT from HLA‐mismatched donors, suggesting that persistent alloimmunity may predispose patients to SSCs. It was recently reported that, in a cohort of patients who received allo‐HSCT from an unrelated donor matched at HLA‐A, ‐B, ‐C, ‐DRB1/3/4/5, and ‐DQB1 loci, HLA‐DPB1 alloimmunity determined by high mismatched eplets (MEs) and Predicted Indirectly Recognizable HLA Epitopes (PIRCHE) score (PS), was associated with relapse protection and increased risk of acute graft‐versus‐host disease (GVHD).

Methods

In the present study, the impact of HLA‐DPB1 alloimmunity assessed by molecular mismatch algorithms on the development of SSCs in a cohort of 1514 patients who underwent allo‐HSCT for hematologic malignancies was further investigated. ME load at the HLA‐DPB1 locus was measured using the HLAMatchmaker module incorporated in HLA Fusion software, and the PS for mismatched HLA‐DPB1 was calculated using the HSCT module from the PIRCHE online matching service.

Results

In multivariable analysis after adjusting for baseline risk factors, higher ME, PS‐I, and PS‐II in the GVH direction, but not in the HVG direction, were associated with an increased risk of SSCs (ME: subdistribution hazard ratio [SHR] 1.58, p = .01; PS‐I: SHR 1.59, p = .009; PS‐II: SHR 1.71, p = .003). In contrast, nonpermissive HLA‐DPB1 mismatches defined by the conventional T‐cell epitope algorithm were not predictive of the risk of SSCs. Moreover, posttransplant cyclophosphamide‐based GVHD prophylaxis was associated with a reduced risk of subsequent solid cancer (SHR 0.34, p = .021).

Conclusions

These results indicate for the first time that increased GVH alloreactivity could contribute to the development of SSCs in allo‐HSCT survivors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationGraft vs Host DiseaseHumansHistocompatibility TestingNeoplasm Recurrence, LocalUnrelated DonorsRetrospective StudiesHLA-DP beta-Chains

Stichwörter der Autor:innen

HLA-DPB1 mismatchallo-HSCTmolecular mismatchposttransplant cyclophosphamidesubsequent solid cancers

Substanzen

HLA-DPB1 antigenHLA-DP beta-Chains

Autor:innen und Institutionen

  • Department of Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Division of Hematology/Oncology, Department of Medicine, Chao Family Comprehensive Cancer Center, University of California, Irvine, California, USA.
  • Center of Excellence in Applied Epidemiology, Faculty of Medicine, Thammasat University, Pathumthani, Thailand.
  • Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Hematology, Soroka University Medical Center, Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva, Israel.
  • Department of Hematopoietic Biology and Malignancy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

ORCID-Profile: Jun Zou, Betül Oran, Samer A Srour, Stefan O Ciurea

Zitieren

APA

Zou, J., Kongtim, P., Oran, B., Srour, S. A., Greenbaum, U., Carmazzi, Y., Rondon, G., Ciurea, S. O., Ma, Q., Shpall, E. J., Champlin, R. E., & Cao, K. (2023). Molecular disparity of HLA‐DPB1 is associated with the development of subsequent solid cancer after allogeneic hematopoietic stem cell transplantation. Cancer. https://doi.org/10.1002/cncr.34671

Vancouver

Zou J, Kongtim P, Oran B, Srour SA, Greenbaum U, Carmazzi Y, et al. Molecular disparity of HLA‐DPB1 is associated with the development of subsequent solid cancer after allogeneic hematopoietic stem cell transplantation. Cancer. 2023. doi:10.1002/cncr.34671

BibTeX
@article{Zou2023,
  author = {Zou, Jun and Kongtim, Piyanuch and Oran, Betül and Srour, Samer A and Greenbaum, Uri and Carmazzi, Yudith and Rondon, Gabriela and Ciurea, Stefan O and Ma, Qing and Shpall, Elizabeth J and Champlin, Richard E and Cao, Kai},
  title = {Molecular disparity of HLA‐DPB1 is associated with the development of subsequent solid cancer after allogeneic hematopoietic stem cell transplantation},
  journal = {Cancer},
  year = {2023},
  doi = {10.1002/cncr.34671}
}
Kostenlos starten →